share_log
Reuters ·  May 2 06:04
Aurinia Pharmaceuticals Inc: Sees Cash Flow Positive, Excluding Share Repurchases, in Q2 2024, With Estimated Cost Savings of $50 to $55 Mln Annually
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment